Elixir Medical bioresorbable stent gets CE mark; Alnylam announces Phase I success for hemophilia med;

> Elixir Medical has received a CE mark for its DESolve 100 novolimus-eluting bioresorbable coronary scaffold, named after its 100-micron strut profile and designed to degrade within a year. It will be available commercially in 2015. Story

> Alnylam ($ALNY) said ALN-AT3, an RNAi treatment for hemophilia and other bleeding disorders, succeeded in a Phase I trial. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.